Patents by Inventor Franck Alexandre Silva
Franck Alexandre Silva has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11779586Abstract: The invention relates to a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and at least one pharmaceutical excipient selected from the group consisting of fillers, binders, disintegrants, glidants and lubricants, wherein the compound according to formula I is represented by:Type: GrantFiled: October 15, 2020Date of Patent: October 10, 2023Assignee: Convalife (Shanghai) Co. LimitedInventors: Stephen Joseph Shuttleworth, Elisabeth Ann Bone, Franck Alexandre Silva, Alexander Richard Liam Cecil
-
Patent number: 11708378Abstract: A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: W is O, N—H, N—(C1-C10 alkyl) or S; each X is independently CH or N; R1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R2 is LY; each L is a direct bond, C1-C10 alkylene, C2-C10 alkenylene or C2-C10 alkynylene; Y is an optionally substituted fused, bridged or spirocyclic non-aromatic 5-12 membered heterocycle containing up to 4 heteroatoms selected from N or O; and each R3 is independently H, C1-C10 alkyl, halogen, fluoro C1-C10 alkyl, O—C1-C10 alkyl, NH—C1-C10 alkyl, S—C1-C10 alkyl, O-fluoro C1-C10 alkyl, NH-acyl, NH—C(O)—NH—C1-C10 alkyl, C(O)—NH—C1-C10 alkyl, aryl or heteroaryl, are useful as inhibitors of the class IA phosphoinositide 3-kinase enzyme, PI3K-p110?, and therefore have potential utility in the therapy of cancer, immune and inflammatory diseases.Type: GrantFiled: March 19, 2021Date of Patent: July 25, 2023Assignee: Convalife (Shanghai) Co. LimitedInventors: Stephen Joseph Shuttleworth, Alexander Richard Liam Cecil, Franck Alexandre Silva
-
Publication number: 20220041624Abstract: A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: W is O, N—H, N—(C1-C10 alkyl) or S; each X is independently CH or N; R1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R2 is LY; each L is a direct bond, C1-C10 alkylene, C2-C10 alkenylene or C2-C10 alkynylene; Y is an optionally substituted fused, bridged or spirocyclic non-aromatic 5-12 membered heterocycle containing up to 4 heteroatoms selected from N or O; and each R3 is independently H, C1-C10 alkyl, halogen, fluoro C1-C10 alkyl, O— C1-C10 alkyl, NH—C1-C10 alkyl, S—C1-C10 alkyl, O-fluoro C1-C10 alkyl, NH-acyl, NH—C(O)—NH—C1-C10 alkyl, C(O)—NH—C1-C10 alkyl, aryl or heteroaryl, are useful as inhibitors of the class IA phosphoinositide 3-kinase enzyme, PI3K-p110?, and therefore have potential utility in the therapy of cancer, immune and inflammatory diseases.Type: ApplicationFiled: March 19, 2021Publication date: February 10, 2022Inventors: Stephen Joseph Shuttleworth, Alexander Richard Liam Cecil, Franck Alexandre Silva
-
Publication number: 20210275537Abstract: The invention relates to a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and at least one pharmaceutical excipient selected from the group consisting of fillers, binders, disintegrants, glidants and lubricants, wherein the compound according to formula I is represented by:Type: ApplicationFiled: October 15, 2020Publication date: September 9, 2021Inventors: Stephen Joseph Shuttleworth, Elizabeth Ann Bone, Franck Alexandre Silva, Alexander Richard Liam Cecil
-
Publication number: 20210038607Abstract: A compound of Formula I: (I) or a pharmaceutically acceptable salt thereof, wherein: each R? is QR1; each Q is independently selected from a bond, —C1-C10 alkylene, —C2-C10 alkenylene, —C(O)—, —C(O)O—, —C(O)N(R1)—, —C(O)N(R1)SO2—N(R1)C(O)—, —N(R1)—, —N(SO2(R1)), —N(R1)SO2—C(O)NR4R5—, —N(R4R5)C(O)—, —N(R4R5)—S—, —SO—, —SO2—, —S(O)O—, —SO2N(R1)— and —O—; each R1 is independently selected from H, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C1-C10 haloalkyl, C1-C10 heteroalkyl, aryl, heteroaryl, C3-C10 cycloalkyl, —(C1-C10 alkylene)-C3-C10 cycloalkyl, halogen, cyano, C1-C10 alkylene-aryl, C1-C10 alkylene heteroaryl, C1-C10 heterocycloalkyl and —(C1-C10 alkylene)-C1-C10 heterocycloalkyl. The compounds are inhibitors of HDAC and therefore have potential utility in the therapy of a number of conditions including cancer and inflammation.Type: ApplicationFiled: March 1, 2019Publication date: February 11, 2021Inventors: Stephen Joseph Shuttleworth, Alice Elizabeth Gatland, Daniel John Finnemore, Rikki Peter Alexander, Franck Alexandre Silva, Alexander Richard Liam Cecil
-
Publication number: 20200354378Abstract: A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: W is O, N—H, N—(C1-C10 alkyl) or S; each X is independently CH or N; R1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R2 is LY; each L is a direct bond, C1-C10 alkylene, C2-C10 alkenylene or C2-C10 alkynylene; Y is an optionally substituted fused, bridged or spirocyclic non-aromatic 5-12 membered heterocycle containing up to 4 heteroatoms selected from N or O; and each R3 is independently H, C1-C10 alkyl, halogen, fluoro C1-C10 alkyl, O—C1-C10 alkyl, NH—C1-C10 alkyl, S—C1-C10 alkyl, O-fluoro C1-C10 alkyl, NH-acyl, NH—C(O)—NH—C1-C10 alkyl, C(O)—NH—C1-C10 alkyl, aryl or heteroaryl, are useful as inhibitors of the class IA phosphoinositide 3-kinase enzyme, PI3K-p110?, and therefore have potential utility in the therapy of cancer, immune and inflammatory diseases.Type: ApplicationFiled: November 8, 2019Publication date: November 12, 2020Inventors: Stephen Joseph Shuttleworth, Alexander Richard Liam Cecil, Franck Alexandre Silva
-
Patent number: 10533003Abstract: The present invention is a compound having the following formula: or a pharmaceutically acceptable salt thereof, wherein e.g. L and Y are each independently an optionally substituted 6-membered nitrogen-containing heteroaryl; M is an optionally substituted 5- to 10-membered heteroaryl; W is a zinc-binding group; each R2 is independently hydrogen or C1-C6 alkyl; and R3 is an aryl or heteroaryl. The compounds are useful as histone deacetylase (HDAC) inhibitors.Type: GrantFiled: October 29, 2015Date of Patent: January 14, 2020Assignee: Karus Therapeutics LimitedInventors: Stephen Joseph Shuttleworth, Alexander Richard Liam Cecil, Somhairle MacCormick, William John Nodes, Cyrille Davy Tomassi, Franck Alexandre Silva
-
Patent number: 10513530Abstract: A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: W is O, N—H, N—(C1-C10 alkyl) or S; each X is independently CH or N; R1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R2 is LY; each L is a direct bond, C1-C10 alkylene, C2-C10 alkenylene or C2-C10 alkynylene; Y is an optionally substituted fused, bridged or spirocyclic non-aromatic 5-12 membered heterocycle containing up to 4 heteroatoms selected from N or O; and each R3 is independently H, C1-C10 alkyl, halogen, fluoro C1-C10 alkyl, O— C1-C10 alkyl, NH—C1-C10 alkyl, S—C1-C10 alkyl, O-fluoro C1-C10 alkyl, NH-acyl, NH—C(O)—NH—C1-C10 alkyl, C(O)—NH—C1-C10 alkyl, aryl or heteroaryl, are useful as inhibitors of the class IA phosphoinositide 3-kinase enzyme, PI3K-p110?, and therefore have potential utility in the therapy of cancer, immune and inflammatory diseases.Type: GrantFiled: April 24, 2018Date of Patent: December 24, 2019Assignee: Karus Therapeutics LimitedInventors: Stephen Joseph Shuttleworth, Alexander Richard Liam Cecil, Franck Alexandre Silva
-
Patent number: 10501478Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein: W is O, N—H, N—(C1-C10 alkyl) or S; each X is independently CH or N; R1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R2 is (LQ)mY; and each R3 is independently H, C1-C10alkyl, aryl or heteroaryl, are surprisingly found to be inhibitors of PI3K-p110?, and therefore have utility in therapy.Type: GrantFiled: March 1, 2018Date of Patent: December 10, 2019Assignee: Karus Therapeutics LimitedInventors: Stephen Joseph Shuttleworth, Alexander Richard Liam Cecil, Thomas James Hill, Franck Alexandre Silva
-
Patent number: 10377764Abstract: The invention relates to a compound of formula I: (I) or a pharmaceutically acceptable salt thereof, wherein each R3 is independently selected from H, halo, fluorinated C1-C10 alkyl, —I—C1-C10 alkyl, —NH—C1-C10 alkyl, —S—C1-C10 alkyl, —O-fluorinated C1-C10 alkyl, —NH-acyl, —NH—C(O)—NH-alkyl, —C—(O)—NH-alkyl, with the proviso that at least one of R3 is not H.Type: GrantFiled: August 19, 2016Date of Patent: August 13, 2019Assignee: Karus Therapeutics LimitedInventors: Stephen Joseph Shuttleworth, Franck Alexandre Silva, Alexander Richard Liam Cecil, Alice Elizabeth Gatland, Daniel John Finnemore
-
Publication number: 20190092790Abstract: A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: W is O, N—H, N—(C1-C10 alkyl) or S; each X is independently CH or N; R1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R2 is LY; each L is a direct bond, C1-C10 alkylene, C2-C10 alkenylene or C2-C10 alkynylene; Y is an optionally substituted fused, bridged or spirocyclic non-aromatic 5-12 membered heterocycle containing up to 4 heteroatoms selected from N or O; and each R3 is independently H, C1-C10 alkyl, halogen, fluoro C1-C10 alkyl, O—C1-C10 alkyl, NH—C1-C10 alkyl, S—C1-C10 alkyl, O-fluoro C1-C10 alkyl, NH-acyl, NH—C(O)—NH—C1-C10 alkyl, C(O)—NH—C1-C10 alkyl, aryl or heteroaryl, are useful as inhibitors of the class IA phosphoinositide 3-kinase enzyme, PI3K-p110?, and therefore have potential utility in the therapy of cancer, immune and inflammatory diseases.Type: ApplicationFiled: April 24, 2018Publication date: March 28, 2019Inventors: Stephen Joseph Shuttleworth, Alexander Richard Liam Cecil, Franck Alexandre Silva
-
Publication number: 20190040079Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein: W is O, N—H, N—(C1-C10 alkyl) or S; each X is independently CH or N; R1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R2 is (LQ)mY; and each R3 is independently H, C1-C10alkyl, aryl or heteroaryl, are surprisingly found to be inhibitors of PI3K-p110?, and therefore have utility in therapy.Type: ApplicationFiled: March 1, 2018Publication date: February 7, 2019Inventors: Stephen Joseph Shuttleworth, Alexander Richard Liam Cecil, Thomas James Hill, Franck Alexandre Silva
-
Publication number: 20180244686Abstract: The invention relates to a compound of formula I: (I) or a pharmaceutically acceptable salt thereof, wherein each R3 is independently selected from H, halo, fluorinated C1-C10 alkyl, —I—C1-C10 alkyl, —NH—C1-C10 alkyl, —S—C1-C10 alkyl, —O-fluorinated C1-C10 alkyl, —NH-acyl, —NH—C(O)—NH-alkyl, —C—(O)—NH-alkyl, with the proviso that at least one of R3 is not H.Type: ApplicationFiled: August 19, 2016Publication date: August 30, 2018Inventors: Stephen Joseph Shuttleworth, Franck Alexandre Silva, Alexander Richard Liam Cecil, Alice Elizabeth Gatland, Daniel John Finnemore
-
Publication number: 20180235974Abstract: The invention relates to a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and at least one pharmaceutical excipient selected from the group consisting of fillers, binders, disintegrants, glidants and lubricants, wherein the compound according to formula I is represented by:Type: ApplicationFiled: August 19, 2016Publication date: August 23, 2018Inventors: Stephen Joseph Shuttleworth, Elizabeth Ann Bone, Franck Alexandre Silva, Alexander Richard Liam Cecil
-
Patent number: 10035785Abstract: A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: R1, R2, R3, R and R6 are each independently (LQ)mY; R4 is H, halogen, optionally substituted aryl or optionally substituted alkyl; and; each X is independently CR7 or N. The compounds are PI3K inhibitors and therefore have potential utility in therapy.Type: GrantFiled: April 25, 2017Date of Patent: July 31, 2018Assignee: Karus Therapeutics LimitedInventors: Stephen Joseph Shuttleworth, Franck Alexandre Silva
-
Patent number: 9981987Abstract: A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: W is O, N—H, N—(C1-C10 alkyl) or S; each X is independently CH or N; R1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R2 is LY; each L is a direct bond, C1-C10 alkylene, C2-C10 alkenylene or C2-C10 alkynylene; Y is an optionally substituted fused, bridged or spirocyclic non-aromatic 5-12 membered heterocycle containing up to 4 heteroatoms selected from N or O; and each R3 is independently H, C1-C10 alkyl, halogen, fluoro C1-C10 alkyl, O—C1-C10 alkyl, NH—C1-C10 alkyl, S—C1-C10 alkyl, O-fluoro C1-C10 alkyl, NH-acyl, NH—C(O)—NH—C1-C10 alkyl, C(O)—NH—C1-C10 alkyl, aryl or heteroaryl, are useful as inhibitors of the class IA phosphoinositide 3-kinase enzyme, PI3K-p110?, and therefore have potential utility in the therapy of cancer, immune and inflammatory diseases.Type: GrantFiled: February 12, 2015Date of Patent: May 29, 2018Assignee: Karus Therapeutics LimitedInventors: Stephen Joseph Shuttleworth, Alexander Richard Liam Cecil, Franck Alexandre Silva
-
Publication number: 20180072699Abstract: A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: R1, R2, R3, R and R6 are each independently (LQ)mY; R4 is H, halogen, optionally substituted aryl or optionally substituted alkyl; and; each X is independently CR7 or N. The compounds are PI3K Inhibitors and therefore have potential utility in therapy.Type: ApplicationFiled: April 25, 2017Publication date: March 15, 2018Inventors: Stephen Joseph Shuttleworth, Franck Alexandre Silva
-
Publication number: 20170313698Abstract: The present invention is a compound having the following formula: or a pharmaceutically acceptable salt thereof, wherein e.g. L and Y are each independently an optionally substituted 6-membered nitrogen-containing heteroaryl; M is an optionallysubstituted 5- to 10-membered heteroaryl; W is a zinc-binding group; each R2 is independently hydrogen or C1-C6 alkyl; and R3 is an aryl or heteroaryl. The compounds are useful as histone deacetylase (HDAC) inhibitors.Type: ApplicationFiled: October 29, 2015Publication date: November 2, 2017Inventors: Stephen Joseph Shuttleworth, Alexander Richard Liam Cecil, Somhairle MacCormick, William John Nodes, Cyrille Davy Tomassi, Franck Alexandre Silva
-
Patent number: 9663487Abstract: A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: R1, R2, R3, R and R6 are each independently (LQ)mY; R4 is H, halogen, optionally substituted aryl or optionally substituted alkyl; and; each X is independently CR7 or N. The compounds are PI3K inhibitors and therefore have potential utility in therapy.Type: GrantFiled: March 8, 2013Date of Patent: May 30, 2017Assignee: Karus Therapeutics LimitedInventors: Stephen Joseph Shuttleworth, Franck Alexandre Silva
-
Publication number: 20160347771Abstract: A compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: W is O, N—H, N—(C1-C10 alkyl) or S; each X is independently CH or N; R1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R2 is LY; each L is a direct bond, C1-C10 alkylene, C2-C10 alkenylene or C2-C10 alkynylene; Y is an optionally substituted fused, bridged or spirocyclic non-aromatic 5-12 membered heterocycle containing up to 4 heteroatoms selected from N or O; and each R3 is independently H, C1-C10 alkyl, halogen, fluoro C1-C10 alkyl, O—C1-C10 alkyl, NH—C1-C10 alkyl, S—C1-C10 alkyl, O-fluoro C1-C10 alkyl, NH-acyl, NH—C(O)—NH—C1-C10 alkyl, C(O)—NH—C1-C10 alkyl, aryl or heteroaryl, are useful as inhibitors of the class IA phosphoinositide 3-kinase enzyme, PI3K-p110?, and therefore have potential utility in the therapy of cancer, immune and inflammatory diseases.Type: ApplicationFiled: February 12, 2015Publication date: December 1, 2016Inventors: Stephen Joseph Shuttleworth, Alexander Richard Liam Cecil, Franck Alexandre Silva